Details for Patent: 12,569,183

Which drugs does patent 12,569,183 protect, and when does it expire?

Patent 12,569,183 protects SOTALOL HYDROCHLORIDE and is included in one NDA.

Summary for Patent: 12,569,183

Title:	Method of administering sotalol IV/switch
Abstract:	Embodiments of the invention are broadly drawn to methods for determining an optimum dose of an antiarrhythmic drug, for example sotalol. In particular, the method involves titrating the dose of the drug gradually to determine the optimum plasma concentration for a patient, whether the patient has normal or abnormal renal function.
Inventor(s):	Vijay Ivaturi, Jogarao Gobburu
Assignee:	University of Maryland Baltimore
Application Number:	US18/156,092
Patent Claim Types: see list of patent claims	Use;

Scope and claims of US Drug Patent 12,569,183 (QTc-guided IV-to-oral switching for class III antiarrhythmics)
US 12,569,183 claims QTc-based decision methods that start with a first intravenous (IV) infusion of a class III antiarrhythmic drug, measure baseline and post-infusion QTc, and then steer dosing toward either (i) continued IV (including a second IV infusion) or (ii) conversion to oral dosing, with escalation, reduction, or discontinuation triggered by QTc (including a >500 msec threshold). The independent claim set is structured around (1) a “delta QTc within a specified range” algorithm and (2) an “absolute QTc prolongation to >500 msec” algorithm, with dependent claims specifying drug identity (sotalol, dofetilide, amiodarone), infusion duration (0.5–2 hours), dosing windows (IV 10–80 mg; oral 80/120/160 mg), and renal-function-based oral interval timing (12 hours for normal renal function; 24 hours for abnormal renal function). A further limitation ties method timing to achieving steady-state maximum plasma concentration within about 24 hours after starting the first IV infusion.

---

What does US 12,569,183 claim for QTc monitoring and IV-to-oral conversion?

Answer: It claims QTc-monitoring methods that determine whether to continue IV infusion or switch to oral administration of class III antiarrhythmics based on (a) delta QTc vs a specified range, or (b) whether QTc prolongs to an absolute threshold (>500 msec), including dosing reduction/discontinuation pathways.

Core structure of the independent method claims

Across the independent claims you provided, the sequencing is consistent:

1. Detect baseline QTc (item a).
2. Administer a dose via a first IV infusion for a first duration (item b).
3. Detect a second QTc after that infusion (item c).
4. Apply a QTc-based rule to decide next steps (item d/e).

The novelty, as reflected in claim scope, sits in the decision rule and the linked dosing actions: IV infusion duration + timing of repeat QTc measurement + conditional selection among oral conversion, second IV infusion, or discontinuation/reduction.

---

What are the key claim elements and what exactly triggers a dosing switch?

Answer: The trigger is either a calculated delta QTc within a specified range (Claim 1) or a QTc prolongation to a fixed >500 msec threshold (Claims 10 and variations). Both triggers control whether further dosing is IV versus oral, and whether the IV must be discontinued or reduced.

Claim 1: “delta QTc within specified range” control logic

Claim 1’s conditional branch is:

• Compute delta QTc = (second QTc measured after first IV infusion) − (baseline QTc).
• If delta QTc is within a specified range:
  • administer a further dose via a second IV infusion for a second duration, or
  • administer at least one oral dose.
• If delta QTc is not within the specified range:
  • discontinue the first IV administration and administer further doses as oral doses or administer reduced second IV dose(s).

Scope notes for enforcement:

• The claim requires baseline QTc and a second QTc after the first IV infusion.
• “Specified range” is not numerically recited in your excerpt; it is an internal parameter of the claim set. That makes claim construction hinge on the patent specification/claims where the “specified range” is defined.
• The “or” structure creates broader infringement pathways: even when delta QTc falls within range, the method can still be practiced by oral conversion alone (no second IV required), or by additional IV.

Claim 10: “absolute QTc >500 msec” threshold control logic

Claim 10 uses a discrete threshold:

• If the second QTc prolongs to >500 msec:
  • discontinue first IV and administer further doses as oral or with reduced second IV dose(s).
• If further QTc does not prolong to >500 msec:
  • administer at least one oral dose or administer a second IV infusion for a second duration.

Scope notes for enforcement:

• “Prolongs to >500 msec” ties the trigger to an absolute post-infusion QTc level rather than a delta.
• Like Claim 1, the claim includes “or” pathways for continued IV reduction/discontinuation and for oral dosing.

Claim 17: threshold-based logic plus steady-state timing

Claim 17 is like the absolute-threshold framework but adds a timing/PK limitation:

• includes condition: if further QTc prolongs to >500 msec then discontinue IV and use oral or reduced second IV.
• if not >500 msec then oral or second IV.
• adds: “the subject achieves steady-state maximum plasma concentration within about 24 hours after initiation of administering the first intravenous infusion.”

Scope notes for enforcement:

• This added limitation narrows claim 17 relative to claims 10/1, because it requires method timing relative to systemic exposure kinetics.
• Practically, it forces an argument that the dosing regimen and PK relationship in the method can produce Cmax at steady state within ~24 hours after starting IV.

---

How broad are the drug-specific limitations (sotalol, dofetilide, amiodarone)?

Answer: Dependent claims explicitly cover three class III antiarrhythmics: sotalol, dofetilide, and amiodarone. The independent claims (as provided) are not limited to a particular drug in the excerpt, but dependent coverage strengthens enforceability for each branded/generic candidate that follows the claimed QTc-guided switching logic.

Dependent claim map for drug identity

• Claim 2: class III antiarrhythmic = sotalol (depends from Claim 1)
• Claim 3: class III antiarrhythmic = dofetilide (depends from Claim 1)
• Claim 4: class III antiarrhythmic = amiodarone (depends from Claim 2 per your numbering text, but substantively it ties amiodarone to the sotalol/dofetilide dependent umbrella in the method family)

For Claim 10 family:

• Claims 11–13 specify sotalol, dofetilide, amiodarone respectively.

For Claim 17 family:

• Claims 18–20 specify sotalol, dofetilide, amiodarone respectively.

Landscape impact:

• Any IV-to-oral protocol for these drugs that uses QTc gating and includes IV infusion first, repeat QTc measurement, then rule-based switching/reduction creates clear claim-to-process mapping risk.

---

What dosing and administration windows are claimed (infusion duration, IV dose, oral dose)?

Answer: The claims recite bounded ranges for administration timing and dosing amounts, including IV infusion duration (0.5–2 hours), IV dose (10–80 mg), and oral dose options (80/120/160 mg).

Infusion duration limitation

• Claim 5: duration of time is 0.5 hour–2 hours.
• Applies as a dependent limitation to Claim 1’s method structure.

IV dose range

• Claim 6: normal or abnormal renal function; IV dose is 10 mg–80 mg (dependent).
• Also appears in the Claim 10 family (Claim 14) and Claim 17 family (Claim 21).

Oral dose set

• Claim 7: oral dose comprises 80 mg, 120 mg, or 160 mg (dependent).
• Also appears in Claim 10 family (Claim 15) and Claim 17 family (Claim 22).

Oral dosing interval depending on renal function

• Claim 8: normal renal function; oral dose is administered at a 12-hour interval from a previous oral dose.
• Claim 9: abnormal renal function; oral dose is administered at a 24-hour interval from a previous oral dose.

This renal-interval pair anchors dosing schedule variations that are often used clinically when clearance differs.

---

How does the “baseline QTc to second QTc” framework map to typical clinical workflows?

Answer: The claims describe a two-point QTc measurement workflow: baseline QTc detection, then QTc detection after a first IV infusion, followed by decision-based continuation, reduction, discontinuation, or conversion to oral dosing.

Minimum required measurement and timing

From your excerpt, the method requires:

• a baseline QTc measurement (before first IV infusion),
• a second QTc measurement after completion of the first IV infusion,
• computation of delta QTc (Claim 1) or evaluation vs >500 msec (Claims 10/17),
• then subsequent dosing actions.

What is “delta QTc” used for?

Claim 1 uses delta QTc to decide whether within a “specified range.” That design allows a spectrum approach (incremental change) rather than a single absolute QTc level.

---

What patent landscape issues matter for freedom-to-operate: process claims vs product claims?

Answer: These are method-of-treatment/process-type claims. For FTO and generic/entry risk, the primary question is whether a competitor can practice the method (directly or through instructions) without falling within each claim’s combined elements: QTc measurement, IV first infusion, timing of second QTc measurement, and conditional switching logic with either delta range or >500 msec thresholds.

Key infringement posture drivers

1. Whether a competitor’s protocol includes the required QTc measurement steps.
2. Whether the regimen includes IV first administration followed by conditional oral conversion.
3. Whether the decision rule matches either the delta range (Claim 1) or >500 msec threshold (Claim 10/17).
4. Whether the dosing and interval details in dependent claims are followed (0.5–2 hours infusion duration, IV 10–80 mg, oral 80/120/160 mg, renal-based 12/24-hour oral intervals).
5. Whether the PK limitation in Claim 17 is satisfied (steady-state Cmax within about 24 hours after IV initiation).

---

How strong is the claim scope based on the claim drafting pattern you provided?

Answer: The claims are drafted as broad conditional algorithms tied to a QTc measurement trigger, with dependent claims adding bounded dosing and timing features. Broadest scope is Claim 1 and Claim 10’s independent logic (delta-range and absolute-threshold pathways). Claim 17 narrows via the steady-state Cmax timing limitation.

Breadth ranking (from what you provided)

1. Broadest: Claim 1 and Claim 10, because both contain the core QTc-guided switching decision tree without the steady-state limitation.
2. Medium: Dependent claims that specify infusion duration, dose ranges, and oral dose options.
3. Narrower: Claim 17 due to the added “steady-state maximum plasma concentration within about 24 hours” requirement.

“Or” branching increases coverage

The conditional “administer… via second IV infusion… or administering oral dose” structure means a protocol that converts to oral dosing even when QTc is acceptable may still practice the claimed method.

---

What generic entry risks exist if a competitor uses the same QTc-guided titration and switching logic?

Answer: Entry risk is highest where an ANDA/505(j) or product-launch plan includes an IV lead-in followed by QTc-triggered conversion to oral dosing using the same QTc thresholds/logic. Even if the competitor’s drug is the same active ingredient, process-driven use claims can still be asserted if the method is practiced.

Risk hotspots

• Protocols that start with IV sotalol/dofetilide/amiodarone, measure QTc baseline and again after infusion, then:
  • reduce IV and/or switch to oral when QTc is above a threshold, or
  • continue IV versus switch based on whether delta QTc is within a range.
• Protocols that follow dosing windows consistent with dependent limitations:
  • first IV infusion within 0.5–2 hours,
  • IV dose in the 10–80 mg range,
  • oral doses 80/120/160 mg,
  • oral intervals 12 hours (normal renal) / 24 hours (abnormal renal).

---

How do claim limitations constrain design-arounds?

Answer: Plausible design-arounds must break at least one required method element or shift the decision rule away from the claimed delta-range/absolute threshold logic, or avoid meeting dependent dosing/timing ranges.

High-leverage design-around levers

• Avoid baseline-to-second QTc comparison as claimed: remove the second QTc measurement after the first IV infusion or use a different clinical endpoint that is not QTc-triggered.
• Use a decision rule not matching the claim:
  • Claim 1 requires delta QTc within a “specified range.”
  • Claim 10/17 require assessment of QTc prolongation to >500 msec (absolute threshold).
• Break IV-first sequencing: use oral-only or non-IV loading strategies before the QTc gating moment.
• Alter dosing schedules so dependent ranges are not met: infusion duration outside 0.5–2 hours, IV dose outside 10–80 mg, oral doses outside 80/120/160 mg, renal-based intervals outside 12/24 hours.
• If litigating claim 17 specifically: shift PK so steady-state Cmax is not reached within about 24 hours after IV initiation.

---

How does this claims set compare with typical QTc management for class III antiarrhythmics?

Answer: The claims institutionalize QTc monitoring and tie it to a two-step, IV-first dosing and then either oral conversion or IV continuation/reduction. Many QTc management practices exist, but these claims are specific to a method that uses baseline QTc, post-IV QTc, and QTc-triggered switching/discontinuation logic with defined dosing/interval features.

Operational differentiation

• The claims require an IV administration step before the QTc-triggered decision outcome.
• They also require a particular QTc decision thresholding scheme (delta within range or >500 msec).

This is materially different from protocols that rely solely on baseline QTc exclusion or general clinician judgment without the two-step QTc measurement and algorithmic switching.

---

What does this mean for a competitor’s Orange Book and FDA pathway exposure (regulatory angle)?

Answer: While Orange Book listings determine patent coverage for approved products, these claims are method claims likely tied to labeled or clinical-use directions. Regulatory submissions can still trigger litigation if the proposed labeling or instructions would cause the patented method to be practiced.

Regulatory-litigation linkage points

• If a competitor’s IV lead-in and QTc-guided switching strategy is reflected in proposed labeling or is otherwise directed to prescribers, method claims become salient.
• Hatch-Waxman Paragraph IV risk typically centers on product patents listed in the Orange Book; however, method claims can still be asserted when they are covered by Orange Book listings or when litigation strategies target instructions that map to the asserted method.

---

Patent estate and claim coverage assessment for US 12,569,183 (based on the provided claim text only)

Answer: The estate scope implied by your claim excerpt is centered on QTc-based IV-to-oral switching for class III antiarrhythmics, with strong coverage of sotalol, dofetilide, and amiodarone, and with moderate to strong coverage of dosing regimens through bounded IV/Oral dose and duration/interval limitations.

What the claim text indicates about “how much is protected”

Protected space includes:

• Patient selection workflow requiring baseline QTc measurement.
• IV lead-in followed by post-infusion QTc detection.
• Rule-based decision:
  • Claim 1: delta QTc in/out of a specified range.
  • Claim 10: QTc >500 msec threshold.
• Dosing outcome options:
  • switch to oral,
  • continue IV with a second infusion,
  • discontinue IV and give oral,
  • reduce second IV dose when QTc exceeds threshold.
• Dosing/time specifics, where dependent:
  • infusion duration 0.5–2 hours,
  • IV dose 10–80 mg,
  • oral doses 80/120/160 mg,
  • renal-based oral dosing interval 12 hours (normal) vs 24 hours (abnormal),
  • and in Claim 17: steady-state Cmax within about 24 hours after IV initiation.

---

Key Takeaways

• US 12,569,183 claims QTc-monitoring methods that use a two-point QTc workflow after a first IV infusion of a class III antiarrhythmic, then conditionally switch to oral dosing or continue/reduce IV dosing.
• The two independent logic branches are: delta QTc within a specified range (Claim 1) and absolute QTc prolongation to >500 msec (Claim 10).
• Dependent claims tightly anchor drug identity to sotalol, dofetilide, and amiodarone and constrain administration with ranges for IV dose (10–80 mg), infusion duration (0.5–2 hours), oral dose options (80/120/160 mg), and renal-based oral intervals (12 vs 24 hours).
• Claim 17 narrows further by requiring that steady-state Cmax is achieved within about 24 hours after IV initiation.
• Generic/competitor entry risk is highest when the launch protocol includes IV-first dosing and a QTc-triggered switching rule that matches the claimed delta/threshold logic and (for dependent coverage) the bounded dosing and interval features.

---

FAQs

1) Does US 12,569,183 require a second QTc measurement after the first IV infusion?

Yes. The method requires detecting a second QTc after the first IV infusion and then using that value in the QTc decision logic.

2) Can the method be practiced using oral dosing alone if QTc is acceptable?

Yes, the independent claim logic includes branches where, when the QTc condition is met, oral dosing can be administered (including as an alternative to a second IV infusion).

3) What is the absolute QTc trigger used in the main threshold-based branch?

The claims as provided use an absolute threshold where QTc prolongation to >500 msec triggers discontinuation of the first IV and switches/redirection of subsequent dosing.

4) Are renal-function dosing intervals part of the claim scope?

Yes. Dependent claims specify 12-hour oral intervals for normal renal function and 24-hour intervals for abnormal renal function.

5) How does the Claim 17 limitation affect method scope?

Claim 17 adds a PK timing constraint requiring steady-state maximum plasma concentration within about 24 hours after initiation of the first IV infusion, narrowing that specific claim.

---

References

1. US Patent No. 12,569,183 (claims as provided in user prompt).

Drugs Protected by US Patent 12,569,183

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Altathera Pharms Llc	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	SOLUTION;INTRAVENOUS	022306-001	Jul 2, 2009		RX	Yes	Yes	12,569,183					METHOD OF ADMINISTERING SOTALOL IV/SWITCH